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with 30 published orthoreovirus 
sequences, including data on all 3 
newly obtained sequences from Pekin 
duck reovirus in China in 2008 and 
2011. Phylogenetic relationship was 
assessed by using the neighbor-joining 
method based on a Tamura 3-parameter 
model and bootstrap analysis (1,000 
replicates) as implemented in MEGA5 
(8). The phylogenetic tree shows that 
the complete sequence of S2 gene 
is distinct but clusters closely with 
sequences from all 3 Pekin duck 
isolates within the ARVs serogroup, 
which suggests that the novel virus 
is an ARV-like virus within the genus 
Orthoreovirus (Figure).
In summary, we isolated a novel 
duck-pathogenic orthoreovirus from 
the liver of affected Pekin ducks. 
The regression test in its natural host 
animal showed that the newly isolated 
virus caused their deaths. This ﬁ  nding 
highlights the need to prevent and 
control this highly transmissible 
infectious agent. Further study is 
needed to determine what role the 
newly isolated DRV played in the 
2011 outbreaks on many of the duck 
farms in China.
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Considerations for 
Oral Cholera 
Vaccine Use 
during Outbreak 
after Earthquake 
in Haiti, 2010–2011
To the Editor: We wish to thank 
Date et al. for their clear discussion of 
the arguments against the use of oral 
cholera vaccines (OCVs) in Haiti in 
2010–11 (1). The epidemic curve in 
their article suggests that the control 
activities had an effect on mortality 
rates, resulting in a decrease in case-
fatality rates to <1%. This ﬁ  nding is 
a remarkable success not achieved 
during the recent cholera outbreak 
in Zimbabwe that affected 98,531 
persons, of whom 4,282 (4.3%) 
died (2). However, the article does 
not discuss the lack of effect of the 
control measures in Haiti on the 
spread of the epidemic. Considering 
the failure of containment, it would 
have been interesting to read how the 
authors judge the recommendation 
not to vaccinate, with the beneﬁ  t of 
hindsight.
The authors list a catalog of 
arguments against the use of OCVs 
in outbreaks. These included the 
priority of water provision and 
cholera treatment measures, how 
modeling data provided no convincing 
justiﬁ   cation for vaccination cam-
paigns, how mobile populations 
cannot be trusted to take 2 doses, the 
time for a 2-dose vaccine to generate 
immunity, the logistic challenges in 
a setting of inadequate infrastructure 
and human resources, the cold 
chain requirements, the difﬁ  culty 
in transport of bulky vaccine, clean 
water requirements for the buffer, civil 
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unrest, and an unpredictable response 
from the public.
Overall, we agree entirely that a 
mass cholera vaccination campaign is 
a massive logistic challenge. We do, 
however, question whether logistic 
challenges of similar size would stop 
vaccination campaigns against, e.g., 
inﬂ   uenza in Hong Kong, People’s 
Republic of China. We are convinced 
that citizens of Hong Kong and their 
advocates would not tolerate such 
arguments regarding challenges. Is 
it because the at-risk population in 
Haiti is perceived to have few, if 
any, powerful advocates that such 
arguments listed by the Centers for 
Disease Control and Prevention and 
the Pan American Health Organization 
could be applied unchallenged?
A much stronger argument 
against vaccinations is the limited 
availability of an appropriate licensed 
vaccine prequaliﬁ  ed for purchase by 
United Nations agencies. At the start 
of the outbreak October 2010, only 
1 OCV, Dukoral (Crucell, Leiden, 
the Netherlands), was licensed and 
prequaliﬁ   ed. However, not even 
300,000 doses of Dukoral were 
available at the start of the outbreak. 
A second OCV, Shanchol (Shantha 
Biotechnics Ltd., Basheerbagh, 
Hyderabad, India), was licensed but 
was prequaliﬁ   ed only in September 
2011. The bigger question is why 
the international agencies failed to 
ensure an appropriate vaccine supply 
following the catastrophic cholera 
outbreak in Zimbabwe in 2008–2009. 
Highly effective OCVs have been 
licensed since 1991 and are marketed 
to afﬂ  uent tourists who are at little, if 
any, risk of being exposed to cholera. 
The neglect of OCVs as a public 
health tool during the past 20 years 
represents a failure of the cholera 
experts and policymakers alike. Again, 
such a failure would be unthinkable 
for a disease affecting more privileged 
population groups.
The authors write that the lack of 
data proving that reactive vaccination 
campaigns are effective was an 
argument against the use of OCVs 
in Haiti. We are in agreement that it 
is unknown whether a reactive mass 
cholera vaccination campaign would 
result in adequate vaccine coverage to 
provide protection and contain further 
spread. There are simply no data. 
It is surprising that the Centers for 
Disease Control and Prevention and 
Pan American Health Organization 
experts did not recognize and use the 
unique opportunity in Haiti to conduct 
mass vaccination campaigns for the 
purpose of collecting such vital data.
Finally, the argument of question-
able cost-effectiveness is mentioned by 
the authors. Indeed, data are lacking on 
the economic beneﬁ  ts of using OCVs 
in severe outbreaks, although their 
cost-effectiveness in cholera-endemic 
situations has been demonstrated (3). 
We believe that anyone who has lived 
through the agonizing indignities of 
a cholera attack, especially during a 
cholera outbreak, would dismiss the 
economic argument out of hand. No 
one should have to suffer, much less 
to die from a vaccine-preventable and 
quickly curable disease. Using the 
argument that vaccinations could be 
too expensive is morally questionable, 
if not to say revolting.
We have arrived at the conclusion 
that the withholding of cholera 
vaccines during the outbreak in Haiti 
in 2010–2011 was a judgment error 
and missed opportunity to collect 
useful data. We wonder whether 
this article was written to justify 
what turns out to be an unsound 
decision, considering the move by 
other agencies to proceed with a pilot 
cholera vaccination campaign (4). We 
believe that persistent neglect of OCV 
as a public health tool is based on the 
shortcomings of the current generation 
of cholera experts and policy makers. 
The long list of technical reasons 
provided by the authors regarding 
why the implementation of mass 
vaccinations was impossible in Haiti 
are plausible excuses. However, the 
true reason that cholera vaccines have 
not been used in Haiti 20 years after 
they have been licensed and shown to 
be effective is the fact that populations 
affected by cholera outbreaks are 
underprivileged, even by the standards 
of impoverished populations. It will 
take decision makers who are less 
risk-averse and more compassionate to 
contain the next cholera outbreak. We 
hope that future decisions will not be 
biased by previous untrue dogma that 
vaccination and other measures such 
as sanitation and effective treatment 
would oppose each other when the 
opposite is true. A more enlightened 
environment would enable more 
widespread use of OCVs.
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In Response: Drs. von Seidlein 
and Deen criticized decisions 
regarding oral cholera vaccine (OCV) 
use in Haiti, but acknowledged that 
there are no data showing that a 
reactive mass OCV campaign would 
contain further disease spread (1). 
They agreed that such a campaign 
is a massive logistic challenge and 
asserted that the limited supply of 
World Health Organization (WHO)–
prequaliﬁ  ed OCV available during the 
ﬁ  rst 11 months of the epidemic in Haiti 
was an even stronger argument against 
vaccination. They then asserted that: 
1) by “withholding” “highly effective” 
OCVs during the outbreak in Haiti, 
an opportunity “to collect data” was 
missed; 2) the decision not to vaccinate 
against cholera “was tolerated” 
because, like other economically 
disadvantaged populations, “Haitians 
have few powerful advocates;” and, 
3) the limited OCV supply represents 
a “failure of the current generation of 
cholera experts and policymakers.” 
In our institutions’ efforts to 
support national authorities, the 
welfare of the Haitian people was and 
remains our primary concern. Our 
publication describes considerations 
during the initial response to an 
expanding epidemic, when the focus 
was on saving lives; recommendations 
were revisited after immediate cholera 
treatment and prevention efforts were 
successfully established. 
As documented in  our report (2) 
and in the media (3,4), the decision 
at the peak of the epidemic to not 
use the available doses of WHO-
prequaliﬁ   ed OCV to vaccinate 
150,000 persons (1.5% of the Haitian 
population) was made by the Haitian 
government, in the setting of well-
publicized differences of opinion 
among experts. Although this decision 
may have resulted in “data not being 
collected,” decisions by sovereign 
governments are rarely overruled 
by international organizations, 
scientists or policymakers. Vaccine 
use without government approval 
would have raised questions about 
the appropriateness of using the 
outbreak to pilot a large-scale reactive 
cholera vaccination campaign without 
documented effectiveness.
OCV effectiveness is moderate 
when compared with measles and 
rubella vaccines. Although vaccine-
preventable diseases, e.g., measles 
and inﬂ  uenza, are primarily prevented 
through vaccination, cholera can be 
prevented and controlled through 
other means.
It is true that underprivileged, 
impoverished populations are 
disproportionately affected by 
epidemic cholera, as they have been 
for centuries. This is not for lack 
of access to OCVs (which are also 
unavailable in the United States), 
but because of lack of access to 
potable water and adequate sanitation. 
OCVs do have a place in cholera 
prevention and response, but a greater 
public health deﬁ   cit underlies the 
spread of cholera in Haiti and other 
countries where it remains endemic 
or epidemic. Ensuring universal 
access to safe water and sanitation, 
beyond recent progress toward 
meeting the Millennium Development 
Goals (5), is vital for global cholera 
control. The Pan American Health 
Organization (PAHO), the United 
Nations Children’s Fund, and the 
Centers for Disease Control and 
Prevention (CDC) have called upon 
the international community to assist 
Haiti in this effort (6).
The issue of OCV availability 
is being addressed by various public 
health organizations. In September 
2011, WHO convened an expert 
consultation to discuss the strategic 
framework for an OCV stockpile 
(7); the second follow-up meeting 
was planned for April 26–27, 2012, 
for further action. Recently, the 
Coalition for Cholera Prevention and 
Control, funded by the Bill & Melinda 
Gates Foundation, held an inaugural 
meeting of cholera and immunization 
experts and policymakers to develop 
comprehensive cholera prevention 
and control strategies that include 
appropriate use of OCVs in endemic 
and epidemic settings (8). Cholera 
outbreaks are unpredictable; increased 
demand from endemic countries can 
ultimately drive vaccine production, 
and help maintain a stockpile for 
outbreak use.
During the past 20 years, a 
substantial effort has been made by 
CDC, WHO, PAHO, and private 
and public partners working with 
governments to provide existing 
vaccines in an equitable manner to 
some of the world’s most disadvantaged 
populations, and to ensure that these 
populations have equal opportunities 
to receive new vaccines, such as 
rotavirus and pneumococcal vaccines 
(9,10). New vaccines require greater 
investments than in the past; criteria 
such as preventable burden, cost-
effectiveness, and sustainability are 
key to systematic, evidence-based 
vaccine introductions (11,12). CDC 
and PAHO are providing technical 
and ﬁ  nancial assistance to the Haitian 
government for improving the 
national vaccine cold chain capacity; 
launching a measles, rubella and polio 
catch-up campaign; and introducing 
pentavalent (diphtheria + tetanus + 
pertussis + Haemophilus inﬂ  uenzae 
type b + hepatitis B), rotavirus, 
and pneumococcal vaccines. With 
approval of the Haitian government, 
CDC and PAHO have provided 
technical assistance to 2 organizations 
implementing small-scale OCV 
campaigns in Haiti.
Contrary to the authors’ suggestion 
of “unquestioned dogma,” the current 
generation of cholera and immunization 
experts and policymakers are engaged 
in developing an evidence-based, 
integrated approach to cholera 
prevention and control that will 
optimize OCV use without neglecting 
either primary prevention through 
improvements in water, sanitation, 
and hygiene, or prevention of cholera-
related deaths through improved access 
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to life-saving treatment. All cholera 
prevention and control measures 
for populations at highest risk need 
the continued support of powerful 
advocates in the scientiﬁ  c,  political, 
and policy-making spheres.
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